Patents by Inventor Christopher KEVIL

Christopher KEVIL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10307441
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: June 4, 2019
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, Anthony Giordano, Douglas R Flanagan, Panayiotis P Constantinides
  • Publication number: 20190062160
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.
    Type: Application
    Filed: April 23, 2018
    Publication date: February 28, 2019
    Inventors: Amol SOIN, Christopher KEVIL, Kyle CHAN, Anthony GIORDANO
  • Publication number: 20180313801
    Abstract: This disclosure describes the use of plasma hydrogen sulfide metabolites as biomarkers for Rheumatoid arthritis, as well as the potential use of these metabolites as therapeutic efficacy targets.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 1, 2018
    Inventors: Christopher KEVIL, Richa DHAWAN, Alexis GUICE
  • Publication number: 20180271802
    Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample.
    Type: Application
    Filed: March 26, 2018
    Publication date: September 27, 2018
    Inventors: Christopher KEVIL, Sibile PARDUE
  • Publication number: 20180275115
    Abstract: The disclosed invention is directed to devices, therapeutics and methods of diagnosing and treating cardio vascular disease in a patient comprising measuring plasma levels of one of free sulfide, acid labile sulfide (ALS), bound sulfane sulfur (BSS), total sulfide metabolites, and some combination thereof, diagnosing, based on plasma levels, the patient with cardio vascular disease, and administering a therapeutically effective dose of a pharmaceutical composition to the patient. According to a further embodiment, the patient is diagnosed with cardio vascular disease if the patient has a polymorphism in a cystathionine gamma-lyase gene but not a cystathionine-beta-synthase gene. According to a further embodiment, the patient is diagnosed with peripheral atrial disease if the patient is African American and the plasma BSS level is significantly lower than an average control plasma BSS level.
    Type: Application
    Filed: March 26, 2018
    Publication date: September 27, 2018
    Inventors: Christopher KEVIL, Matthew DESHOTELS
  • Publication number: 20170349438
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.
    Type: Application
    Filed: June 6, 2017
    Publication date: December 7, 2017
    Inventors: Amol SOIN, Christopher KEVIL, Kyle CHAN, Anthony GIORDANO
  • Publication number: 20170312310
    Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.
    Type: Application
    Filed: April 10, 2017
    Publication date: November 2, 2017
    Inventors: Christopher Kevil, David Lefer, Rakesh Patel
  • Publication number: 20170224725
    Abstract: A method of treating neuropathy in a subject, the method comprising identifying a subject who has neuropathy; and administering to the subject a pharmaceutical composition comprising one of inorganic nitrite and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 23, 2017
    Publication date: August 10, 2017
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Christopher KEVIL
  • Publication number: 20170143759
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.
    Type: Application
    Filed: January 5, 2017
    Publication date: May 25, 2017
    Inventors: Christopher KEVIL, Kyle CHAN, Amol SOIN
  • Patent number: 9649334
    Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: May 16, 2017
    Assignees: The UAB Research Foundation, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, David Lefer, Rakesh Patel
  • Patent number: 9579344
    Abstract: Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: February 28, 2017
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical college
    Inventor: Christopher Kevil
  • Patent number: 9561249
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: February 7, 2017
    Assignee: TheraVasc Inc.
    Inventors: Christopher Kevil, Kyle Chan, Amol Soin
  • Publication number: 20160146807
    Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Christopher KEVIL, Robert McVIE, John GLAWE
  • Publication number: 20160067279
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.
    Type: Application
    Filed: September 8, 2015
    Publication date: March 10, 2016
    Inventors: Christopher Kevil, Anthony Giordano, Douglas R. Flanagan, Panayiotis P. Constantinides
  • Patent number: 9234886
    Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 12, 2016
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, Robert McVie, John Glawe
  • Publication number: 20150233896
    Abstract: Hydrogen sulfide (H2S) levels in plasma are useful in diagnosing cardiovascular disease. The ratio of H2S to NO in plasma is useful in diagnosing peripheral artery disease.
    Type: Application
    Filed: October 22, 2013
    Publication date: August 20, 2015
    Applicant: LSU System Office
    Inventors: Christopher KEVIL, Elvis A. PETER, Xinggui SHEN
  • Publication number: 20150196588
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.
    Type: Application
    Filed: February 19, 2015
    Publication date: July 16, 2015
    Inventors: Christopher KEVIL, Kyle CHAN, Amol SOIN
  • Publication number: 20150110899
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Christopher KEVIL, Anthony GIORDANO
  • Publication number: 20140242194
    Abstract: Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.
    Type: Application
    Filed: December 12, 2013
    Publication date: August 28, 2014
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical college
    Inventor: Christopher KEVIL
  • Publication number: 20140112983
    Abstract: The present invention relates to compositions of nitrite and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition of inorganic nitrite, or a pharmaceutically acceptable salt thereof, for supplementation in subjects with diabetes, peripheral artery diseases or in patients with risk factors associated with cardiovascular diseases.
    Type: Application
    Filed: April 13, 2012
    Publication date: April 24, 2014
    Applicant: TheraVasc Inc.
    Inventors: Anthony Giordano, Christopher Kevil, Paul Sonz, James Douglas Boudreaux